Find A PhysicianHome  |  Library  |  myDownstate  |  Newsroom  |  A-Z Guide  |  E-mail  |  Contact Us  |  Directions
curve gif

Faculty

« Previous | Next »


Photo

Sofya Glazman

Study Coordinator

Department of Neurology

Tel: (718) 270-7371 Fax: (718) 221-5381

e-mail: Sofya.Glazman@downstate.edu

Background and Expertise:

Research coordinator. Seeing research participants.

 

Research Interests:
  • Parkinson disease and Related Movement Disorders

 

Education and training:
  • CCRP (Certified Clinical Research Professional)

 

Clinical Trials In Progress:

 

Osmotica Pharmaceutical Corp. A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson’s Disease

Subjects with Levodopa-Induced Dyskinesias.

 

A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson’s Disease Subjects with Levodopa-Induced Dyskinesias. The purpose of these studies is to compare the efficacy and safety of two different dose levels of Amantadine Extended Release tablets to placebo for the treatment of levodopa-induced dyskinesias in patients with PD. Civitas Therapeutics, a wholly owned subsidiary of Acorda Therapeutics, Inc.

 

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT­301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™).

 

Sub-study: Video recording for training and assessment.

 

A 12-Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena).

 

Sub-study: Video recording for training and assessment.

 

The studies will review the usefullness and safety of an investigational drug, inhaled CVT 301, compared with placebo in PD patients suffering from motor response fluctuations (OFF episodes) at home and in the clinic.

  • Rieger JW, Kim A, Argyelan M, Farber M, Glazman S, Liebeskind M, Bodis-Wollner I. Cortical Control of Voluntary Saccades in Parkinson’s Disease. Clin EEG and Neurosci. 2008 39(4):169-174. PMID: 19044213
  • NINDS NET-PD Investigators (2008) A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease: 18-Month Results . Clin Neuropharmacol.2008 May-Jun;31(3):141-150. doi: 10.1097/WNF.0b013e3181342f32.             PMID: 18520981

  • Hajee ME , March WF , Lazzaro DR , Wolintz AH , Shrier EM , Glazman S , Bodis-Wollner IG . Inner Retinal Layer Thinning in Parkinson Disease. Arch Ophthalmol. 2009;127(6):737-741.  doi: 10.1001/archophthalmol.2009.106.             PMID: 19506190

  • Shrier EM,  Adam CR, Spund B, Glazman S,   Bodis-Wollner I .  Interocular asymmetry of foveal thickness in Parkinson Disease. J Ophthalmol. 2012; 2012:728457. doi: 10.1155/2012/728457. Epub 2012 Aug 1.        PMID: 22900149

  • Javaid MA, Amassian V, Glazman S, Fesharaki A, Stefanov D, Bodis-Wollner I. Cortical control of voluntary saccades in Parkinson's disease and pre-emptive perception. Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S100-3. doi: 10.1016/S1353-8020(11)70032-3. PMID: 22166401

  • Elm JJ; The NINDS NET-PD Investigators. Design Innovations and Baseline Findings in a Long-Term Parkinson’s Trial: The National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson’s Disease Long-Term Study-1. Mov Disord. 2012 Oct;27(12):1513-1521. doi: 10.1002/mds.25175.           PMID: 23079770

  • Yerram S, Glazman S, Bodis-Wollner I . Cortical control of saccades in Parkinson Disease and Essential Tremor. J Neural Transm. 2013 Jan;120(1):145-156. doi: 10.1007/s00702-012-0870-3. Epub 2012 Aug 28.    PMID: 22926662

  • Spund B,  Ding Y,   Liu T, Selesnick I, Glazman S, Shrier EM, Bodis-Wollner I.   Remodeling of the fovea in Parkinson disease. J Neural Transm. 2013 May;120(5):745-753. doi: 10.1007/s00702-012-0909-5. Epub 2012 Dec 23.        PMID: 23263598

  • Bodis-Wollner I , Glazman S, Yerram S. Fovea and foveation in Parkinson Disease. Behav Neurosci. 2013 Apr;127(2):139-150. doi: 10.1037/a0031225. Epub 2013 Jan 28.PMID:23356330

  • Adam CR, Shrier E, Bodis-Wollner I, Ding Y, Glazman S.  Correlation of inner retinal thickness evaluated by spectral-domain optical coherence tomography and contrast sensitivity in Parkinson disease. J Neuroophthalmol. 2013 Jun;33(2):137-142. doi: 10.1097/WNO.0b013e31828c4e1a. PMID: 23612240

  • Bodis ‐ Wollner I, Miri S, Glazman S. Venturing into the no ‐ man's land of the retina in Parkinson's disease. Mov Disord. 2014 Jan;29(1):15-22. doi: 10.1002/mds.25741. Epub 2013 Dec 11. PMID: 24339212 

  • Parkinson Study Group QE3 Investigators.  A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit.JAMA Neurol. 2014 May;71(5):543-52. doi: 10.1001/jamaneurol.2014.131. PMID:24664227

  • Ding Y, Spund B, Glazman S, Shrier EM, Miri S, Selesnick I, and Bodis-Wollner I. Application of an OCT data-based mathematical model of the foveal pit in Parkinson Disease . J Neural Transm. 2014 Nov;121(11):1367-1376. doi: 10.1007/s00702-014-1214-2. Epub 2014 Apr 20.

    PMID: 24748549 

  • Bodis-Wollner I, Kozlowski PB, Glazman S, Miri S. Alpha-synuclein in the inner retina in Parkinson’s Disease. Ann Neurol. 2014 Jun;75(6):964-966. doi: 10.1002/ana.24182. Epub 2014 Jun 13. PMID: 24816946

  • Miri S, Shrier EM, Glazman S, Ding Y, Selesnick I, Kozlowski PB, Bodis ‐ Wollner I. The avascular zone and neuronal remodeling of the fovea in Parkinson disease. Ann Clin Transl Neurol. 2015 Feb;2(2):196-201. doi: 10.1002/acn3.146. Epub 2015 Jan 8. PMID: 25750923

  • Westheimer O , McRae C , Henchcliffe C , Fesharaki A , Glazman S , Ene H , Bodis-Wollner I . Dance for PD: A Preliminary Investigation of effects on Motor Function and Quality of Life among Persons with Parkinson’s Disease (PD). J Neural Transm. 2015 Sep;122(9):1263-1270. doi: 10.1007/s00702-015-1380-x. Epub 2015 Apr 3. PMID:25836752

  • A Multi-Center, Randomized Double-Blind, Phase II Study of Pioglitazone in Early Parkinson’s Disease” Lancet Neurology. Published Online:23 June 2015.doi:10.1016/S1474-4422(15)00144-1 .

  • Bega D, Lou S, Fernandez H, Chou K, Aminoff M, Parashos S, Walker H, Russell D, Christine C, Dhal R, Singer   C, Bodis-Wollner I, Nicholas A, Hamill R, Truong D, Mari Z, Glazman S, Houston E, Simuni T, on behalf of the NET-PD LS1 Investigators.   Impact of depression on progression of impairment and disability in early Parkinson disease.    The NET-PD LS1 cohort. Mov Disord Clin Pract 2015. Vol. 30, Suppl. 1, 2015, pp. S568–S633. 2015 International Parkinson and Movement Disorder Society . doi:10.1002/mdc3.12205
  • Slotnick S, Ding A, Glazman S, Durbin M, Miri S, Selesnick I, Bodis-Wollner I, A Novel Retinal Biomarker for Parkinson’s Disease: Quantifying the Foveal Pit with Optic Coherence Tomography. Mov Disord 2015 Oct; Vol 30 (12): 1692-1695. Article first published online: 4 SEP 2015; DOI: 10.1002/mds.26411.

  • Miri S, Glazman S, Mylin L, Bodis-Wollner I. A combination of retinal morphology and visual electrophysiology testing increases diagnostic yield in Parkinson’s disease.  Parkinsonism Relat Disord. 2016 Jan; 22, Suppl 1: S134-S137. doi: http://dx. doi:10.1016/j.parkreldis.2015.09.015

  • Miri S, Glazman S, Bodis-Wollner I. OCT and Parkinson’s Disease. In Grzybowski A &   Barbonu P, Editors, OCT in Central Nervous System DiseasesSpringer. Under publication.